Wells Fargo (WFC) offers 10‑year notes at 5.15% — $1,000 par, callable
Rhea-AI Filing Summary
Wells Fargo (WFC) is offering senior unsecured Medium-Term Notes, Series AA, with a stated maturity of May 14, 2036 and a fixed interest rate of 5.15% per annum payable semi‑annually. The principal amount per note is $1,000; original offering price is $1,000 per note, with certain institutional and fee‑based advisory account purchases priced between $980.00 and $1,000.00. Notes are redeemable at Wells Fargo's option on specified annual dates beginning May 14, 2028 through May 14, 2035, at 100% of principal plus accrued interest; any redemption may be subject to prior regulatory approval. The notes are senior unsecured obligations, not FDIC insured, not listed on any exchange, and subject to Wells Fargo's credit risk. The agent discount may be up to $20.00 per note, leaving proceeds to Wells Fargo of $980.00 per note based on the maximum agent discount shown.
Positive
- None.
Negative
- None.
Insights
Fixed‑rate medium‑term notes with issuer call; investors face issuer credit and liquidity risk.
The structure is a 10‑year fixed‑rate note at 5.15% with annual issuer optional redemption windows starting in 2028. The issuer call at par means reinvestment risk if market rates decline and Wells Fargo exercises the call; any redemption also may require regulatory approval.
Secondary market liquidity is limited because the notes will not be listed; prospective buyers should note the $20.00 agent discount and projected hedging costs embedded in secondary prices. Timing of redemptions and credit developments in Wells Fargo's disclosures are the primary items to watch in future filings.
Notes are expected to be treated as debt for U.S. federal income tax purposes.
Counsel opines the notes will be debt instruments and typically issued without original issue discount if issue price equals stated principal amount. If issue price differs materially from principal, the notes could carry OID, altering current income recognition for U.S. holders.
Monitor the final pricing disclosure on the pricing date for confirmation of the issue price and any OID treatment disclosed in the prospectus supplement.